Department of Microbiology, College of Natural Sciences, Pusan National University, Busan 609-735, Republic of Korea.
Cancer Lett. 2013 Jul 28;335(2):372-9. doi: 10.1016/j.canlet.2013.02.057. Epub 2013 Mar 6.
Aberrant promoter methylation of tumor suppressor genes including retinoic acid receptor-β2 (RAR-β2) is frequently detected in hepatitis C virus (HCV)-associated hepatocellular carcinoma; however, the mechanism and its significance are relatively unknown. Here, we showed that HCV Core induced promoter hypermethylation of RAR-β2 to inhibit its expression via up-regulation of DNA methyltransferases 1 and 3b. Under the condition, all-trans retinoic acid (ATRA) failed to activate p16 expression and thus could not inactivate the Rb-E2F pathway. Accordingly, Core-expressing cells exhibited resistance to ATRA-induced growth inhibition. Taken together, HCV Core antagonizes ATRA, a natural anti-cancer compound, to stimulate cell growth via epigenetic down-regulation of RAR-β2.
肿瘤抑制基因包括维甲酸受体-β2(RAR-β2)的启动子异常甲基化在丙型肝炎病毒(HCV)相关的肝细胞癌中经常被检测到;然而,其机制及其意义尚不清楚。在这里,我们表明 HCV Core 通过上调 DNA 甲基转移酶 1 和 3b 诱导 RAR-β2 的启动子超甲基化,从而抑制其表达。在这种情况下,全反式维甲酸(ATRA)不能激活 p16 的表达,因此不能使 Rb-E2F 通路失活。因此,表达 Core 的细胞对 ATRA 诱导的生长抑制表现出抗性。总之,HCV Core 通过表观遗传地下调 RAR-β2 拮抗 ATRA(一种天然的抗癌化合物)来刺激细胞生长。